抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的关键问题:再读共识

The Crucial Problems in the Treatment of Crohn's Disease with Anti-tumor Necrosis Factor-α Monoclonal Antibody

炎症性肠病是一组病因尚不十分明确的慢性非特异性肠道炎症性疾病,包括溃疡性结肠炎和克罗恩病,以抗肿瘤坏死因子α单克隆抗体为代表的生物制剂在炎症性肠病中主要用于治疗克罗恩病。《抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)》在本期发布,通过再读新版共识,重点探讨抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的部分关键问题,以帮助临床医生提高认识。

Inflammatory bowel diseases,including ulcerative colitis and Crohn’s disease,are chronic non-specific inflammatory diseases of bowels whose etiology is not clear. Anti-tumor necrosis factor （TNF） -a mono-clonal antibody is one of the representative biological agents used for the treatment of Crohn’s disease. The “2017 revised Consensus on the Anti- TNF-a Monoclonal Antibody Therapy of Inflammatory Bowel Disease” will be pub-lished in current issue. From reviewing the new consensus,the author discussed some key points of anti- TNF-a monoclonal antibody therapy in Crohn’s disease,hoping to improve clinical practice of anti- TNF-a monoclonal an-tibody therapy in Crohn’s disease.